Where are we with treatment options after first line in small cell lung cancer?—report of two opposite cases treated with CAPTEM regimen and possible perspectives

With platinum-etoposide doublets, oncologists have long been used to “play it safe” in first line setting of extensive disease small cell lung cancer (ed-SCLC) patients. Instead second line treatment was historically considered a stumbling block, hard to handle both for patients and clinicians, where all the expectations are quickly disappointed.